LXRX · Lexicon Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio
$1.88
-0.01 (-0.27%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$798.70M
Shares
444.96M
Volume · Sep 30
1.74M
Avg daily vol (3M)
2.96M
Lexicon Pharmaceuticals, Inc. Earnings Call Transcripts
Quarterly earnings calls for Lexicon Pharmaceuticals, Inc. (LXRX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲69.6%
$39,000
−$23.39M
'22 Q3
22-11-09
·
$24,000
−$31.93M
'23 Q1
23-05-02
▲805.7%
$317,000
−$44.90M
'23 Q2
23-08-03
▲315.4%
$162,000
−$50.52M
'23 Q3
23-11-08
▲4608.3%
$1.13M
−$48.40M
'24 Q1
24-05-02
·
$701,000
−$49.76M
'23 Q4
24-05-03
▲419.6%
$1.65M
−$53.43M
'24 Q2
24-08-01
▲980.2%
$1.75M
−$64.81M
'24 Q3
24-11-22
▲3688%
$26.55M
−$33.77M
'24 Q4
25-03-06
▲11.7%
$1.26M
−$25.30M
'25 Q1
25-05-13
▲1652.6%
$28.87M
$3.25M
'25 Q2
25-08-06
▲710.4%
$14.18M
−$12.77M
'25 Q3
25-11-06
▼79.3%
$5.49M
−$15.53M
'25 Q4
26-03-05
▲1572.1%
$21.10M
−$1.04M
'26 Q1
26-05-07
LATEST
▼97.6%
$692,000
−$31.77M
'26 Q2
26-08-06
Conference
Investor event
2026-09-14
Lexicon Pharmaceuticals, Inc. (LXRX) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Confident tone
Zynquista (sotagliflozin) NDA Resubmission
Sotagliflozin Mechanism and HCM Differentiation
Forward-Looking Risks / Regulatory Dependence
Revenue
$692,000
▼ 97.6% YoY Diluted EPS
$-0.07
▼ 800% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Lexicon Pharmaceuticals, Inc. (LXRX) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Confident tone
Sodagliflozin in HCM (SONATA Phase 3)
LX9851 / Novo Nordisk collaboration in obesity
Financial position & operational discipline
Revenue
$21.10M
▲ 1572.1% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript
Confident tone
Sodagliflozin in HCM (Sonata Phase 3)
Mechanism of action / SGLT1 differentiation
LX9851 obesity program with Novo Nordisk
Revenue
$5.49M*
▼ 79.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript
Positive tone
SONATA Phase III trial in HCM
Pilavapadin (DPNP) Phase III readiness and partnering
Zynquista FDA path forward in type 1 diabetes
Revenue
$14.18M
▲ 710.4% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript
Confident tone
Sotagliflozin (SOTA) in HCM (Sonata Phase 3)
Pilavapidin in neuropathic pain (DPNP)
Competitive landscape / NAV inhibitors in pain
Revenue
$28.87M
▲ 1652.6% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript
Confident tone
Pilavapadin Phase 3 path for DPNP
Sotagliflozin SONATA HCM pivotal study
Clinical trial enrollment environment
Revenue
$1.26M
▲ 11.7% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call
Revenue
$26.55M*
▲ 3688% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-22
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript
Balanced tone
Sotagliflozin pipeline: SONATA HCM Phase 3
LX9211 Phase 2b in diabetic peripheral neuropathic pain
ZYNQUISTA FDA AdCom and PDUFA decision
Revenue
$1.75M
▲ 980.2% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript
Positive tone
Zynquista NDA resubmission and Type 1 diabetes launch
INPEFA commercial performance in heart failure
Sotagliflozin pipeline expansion (HCM, neuropathic pain)
Revenue
$1.65M
▲ 419.6% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-05-03
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2023 Earnings Call
Revenue
$701,000*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q1
2024-05-02
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
Positive tone
Zynquista Type 1 Diabetes NDA Resubmission
INPEFA Heart Failure Commercial Launch
Sotagliflozin Label Expansion into HCM
Revenue
$1.13M
▲ 4608.3% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q3
2023-11-08
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2023 Earnings Call Transcript
Revenue
$162,000
▲ 315.4% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2023 Earnings Call Transcript
Revenue
$317,000
▲ 805.7% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2023 Earnings Call Transcript
Revenue
$24,000
Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call Transcript
Revenue
$39,000
▲ 69.6% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2022 Earnings Call Transcript
Revenue
$35,000
▼ 85% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2021 Earnings Call Transcript
Revenue
$14,000*
▼ 93% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2021 Earnings Call Transcript
Revenue
$23,000
▼ 99.7% YoY Diluted EPS
$-0.16
▼ 122.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-30
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2021 Earnings Call Transcript
Revenue
$234,000
▼ 97.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2021 Earnings Call Transcript
Revenue
$27,000
▼ 99.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-10
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2020 Earnings Call Transcript
Revenue
$199,000*
▼ 97.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2020 Earnings Call Transcript
Revenue
$6.63M
▼ 97.7% YoY Diluted EPS
$0.71
▼ 63.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2020 Earnings Call Transcript
Revenue
$9.16M
▼ 5.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-27
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2020 Earnings Call Transcript
Revenue
$8.00M
▼ 13.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2019 Earnings Call
Revenue
$8.73M
▼ 48.9% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls